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OBJECTIVE—Phosphorylation of two members of the TBC1
domain family of proteins, Akt substrate of 160 kDa (AS160, also
known as TBC1D4) and TBC1D1, has been implicated in the
regulation of glucose transport in skeletal muscle. Insulin-stim-
ulated phosphorylation (measured using the phospho-Akt sub-
strate [PAS] antibody) of AS160 and TBC1D1 appears to occur in
an Akt-dependent manner, but the kinases responsible for con-
traction-stimulated PAS-AS160 and PAS-TBC1D1 remain unclear.
AMP-activated protein kinase (AMPK) and Akt, both activated by
contraction, can each phosphorylate AS160 and TBC1D1 in
cell-free assays.
RESEARCH DESIGN AND METHODS—To evaluate the roles
of AMPK and Akt on insulin- or contraction-stimulated PAS-
AS160, PAS-TBC1D1, and glucose transport, rat epitrochlearis
was incubated with and without compound C (inhibitor of
AMPK) or Wortmannin (inhibitor of phosphatidylinositol [PI]
3-kinase, which is upstream of Akt) before and during insulin
stimulation or contraction.
RESULTS—Insulin-stimulated glucose transport and phosphor-
ylation of both AS160 and TBC1D1 were completely inhibited by
Wortmannin. Wortmannin eliminated contraction stimulation of
phospho-Ser
21/9glycogen synthase kinase 3/ (pGSK3; Akt sub-
strate) and PAS-AS160 but did not signiﬁcantly alter pAMPK,
phospho-Ser
79acetyl CoA carboxylase (pACC; AMPK substrate),
PAS-TBC1D1, or glucose transport in contraction-stimulated
muscle. Compound C completely inhibited contraction-stimu-
lated pACC and PAS-TBC1D1 and partially blocked glucose
transport, but it did not signiﬁcantly alter pAkt, pGSK3, or
PAS-AS160.
CONCLUSIONS—These data suggest that 1) insulin stimulates
glucose transport and phosphorylation of AS160 and TBC1D1 in
a PI 3-kinase/Akt–dependent manner, 2) contraction stimulates
PAS-AS160 (but not PAS-TBC1D1 or glucose transport) in a PI
3-kinase/Akt–dependent manner, and 3) contraction stimulates
PAS-TBC1D1 and glucose transport (but not PAS-AS160) in an
AMPK-dependent manner. Diabetes 58:1096–1104, 2009
I
nsulin and contractile activity, the two most impor-
tant physiological stimuli that increase glucose
transport in skeletal muscle, can each induce the
translocation of GLUT4 glucose transporters from
the cell’s interior to its surface membranes (1,2). However,
they regulate glucose transport via distinct signaling path-
ways (3). Insulin-stimulated glucose transport requires
phosphatidylinositol (PI) 3-kinase activation, which leads
to Akt activation without stimulating AMP-activated pro-
tein kinase (AMPK) (3–6). A great deal of evidence sug-
gests that contraction stimulates glucose transport by a
mechanism independent of PI 3-kinase/Akt (7–10) and
attributable to the effects of multiple inputs, with AMPK-
and calcium-mediated processes being major factors
(11,12).
In 3T3-L1 adipocytes, insulin stimulates phosphoryla-
tion of Akt substrate of 160 kDa (AS160; also called
TBC1D4) in an Akt-dependent manner on sites identiﬁable
by the phospho-Akt substrate (PAS) antibody (13,14).
AS160 includes a Rab GTPase-activating protein domain
(RabGAP) that inhibits Rab proteins involved in regulating
vesicular trafﬁc (15). The insulin-mediated increase in PAS
phosphorylation of AS160 (PAS-AS160) appears to inhibit
RabGAP activity, thereby allowing GLUT4 to be recruited
to surface membranes and elevate glucose transport (14–
17). In skeletal muscle, insulin or contraction results in
elevated PAS-AS160 (18,19), and AS160 phosphorylation
appears to regulate glucose transport (20).
Recently, TBC1D1, a RabGAP protein paralog to AS160,
was also shown to become PAS-phosphorylated (PAS-
TBC1D1) in response to insulin in an Akt-dependent
manner (21). However, whereas AS160 knockdown in
3T3-L1 adipocytes resulted in elevated basal cell-surface
GLUT4 (17,22), TBC1D1 knockdown had no effect on basal
cell-surface GLUT4 in 3T3-L1 cells (23). TBC1D1 protein is
only 5% as abundant as AS160 protein in 3T3-L1 adipo-
cytes, which may explain why TBC1D1 does not appear to
play a major role in regulating glucose transport in these
cells (23). TBC1D1 protein abundance is much greater in
skeletal muscle versus adipose tissue (24), and silencing
TBC1D1 in L6 myotubes resulted in increased basal cell-
surface GLUT4 (25), supporting the idea that TBC1D1
inhibits GLUT4 translocation in the basal state. However,
in contrast to the results for L6 cells with AS160 knock-
down (which did not alter the insulin-stimulated net
increase in cell-surface GLUT4), silencing TBC1D1 in L6
cells resulted in greater insulin-induced GLUT4 transloca-
tion versus control cells (25). In other words, TBC1D1
knockdown allowed insulin to induce a greater amount of
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These ﬁndings suggest that at least a portion of the
inhibitory effects of TBC1D1 on GLUT4 may not be
restrained by insulin. However, they do not eliminate the
possibility that TBC1D1 can regulate an insulin-indepen-
dent increase in glucose transport (e.g., with contraction).
PAS-TBC1D1 is elevated in response to contraction in
rodent skeletal muscle (19,24). Therefore, it seems possi-
ble that PAS-TBC1D1 may play a role in mediating con-
traction-stimulated glucose transport.
Experiments using puriﬁed Akt or AMPK demonstrated
that each kinase can phosphorylate both AS160 and
TBC1D1 in cell-free assays (26,27). Considerable evidence
indicates that the insulin-stimulated increase in PAS-
AS160 is Akt dependent in skeletal muscle (18,28), and
increased AS160 phosphorylation appears to be important
for the full effect of insulin on glucose transport (20).
However, the speciﬁc kinases responsible for contraction-
stimulated PAS-AS160 need to be clariﬁed because: 1)
Wortmannin can completely inhibit the contraction-stim-
ulated increase in PAS-AS160 in rat skeletal muscle, sug-
gesting that Akt is responsible for the increased PAS-
phosphorylation of AS160 during contraction (18), but 2)
muscles from mice with genetically disrupted AMPK ver-
sus wild-type littermates had reduced contraction-stimu-
lated increase in immunoreactivity toward PAS antibody
at 160 kDa (PAS-160) (28,29).
The primary aim of this study was to elucidate the
contributions of Akt and AMPK on increases in PAS-AS160
and PAS-TBC1D1 in skeletal muscle stimulated by insulin
or contraction. The PI 3-kinase inhibitor Wortmannin was
used to prevent Akt activation (without altering AMPK
activation), and compound C, a potent AMPK inhibitor
(30), was used to prevent AMPK activation (without
altering Akt activation). A secondary aim was to determine
whether inhibition of insulin- or contraction-stimulated
increases in PAS-AS160 or PAS-TBC1D1 was accompanied
by attenuated insulin- or contraction-stimulated glucose
transport. We hypothesized that in isolated rat epitrochle-
aris muscle: 1) Akt-dependent mechanisms are essential
for the insulin-stimulated increases in glucose transport
and phosphorylation of AS160 and TBC1D1; 2) Akt-depen-
dent (but not AMPK-dependent) mechanisms are essential
for contraction-stimulated increases in PAS-AS160, but not
glucose transport; and 3) AMPK-dependent (but not Akt-
dependent) mechanisms are essential for contraction-
stimulated increases in PAS-TBC1D1 (but not PAS-AS160)
and glucose transport.
RESEARCH DESIGN AND METHODS
Human recombinant insulin was obtained from Eli Lilly (Indianapolis, IN).
Wortmannin was purchased from Sigma-Aldrich (St. Louis, MO). Compound C
was from EMD Chemicals (San Diego, CA). Reagents for SDS-PAGE and
immunoblotting, including Precision Plus Protein dual-color standards, were
from Bio-Rad (Hercules, CA). Bicinchoninic acid protein assay reagent, T-PER
tissue protein extraction reagent, and West Dura extended duration substrate
were from Pierce Biotechnology (Rockford, IL). Anti–phospho-Thr
308Akt
(pAkt), anti–phospho-Ser
21/9glycogen synthase kinase 3/ (pGSK3), anti-
GSK3, anti–phospho-Thr
172AMPK (pAMPK), anti-AMPK, anti–phospho-
Ser
79acetyl CoA carboxylase (pACC), anti-ACC, anti–phospho-Thr
286Ca
2/
calmodulin-dependent kinase II (pCaMKII), anti-CaMKII, anti–phospho-(Ser/
Thr) Akt substrate (PAS; which was designed to recognize Akt
phosphorylation motif peptide sequences [RXRXXpT/S]), and goat anti-rabbit
IgG HRP conjugate were from Cell Signaling Technology (Danvers, MA).
TBC1D1 polyclonal antibody was provided by Dr. Jianxin Xie (Cell Signaling
Technology). AS160 antibody was from Millipore (Billerica, MA). Anti-Akt1/
2/3, Preclearing Matrix F, and ExactaCruz F-HRP were from Santa Cruz
Biotechnology (Santa Cruz, CA). 3-O-methyl-[
3H]glucose ([
3H]3-MG) was from
Sigma-Aldrich, and [
14C]mannitol was from Perkin Elmer (Waltham, MA).
Other reagents were from Sigma-Aldrich or Fisher Scientiﬁc (Pittsburgh, PA).
Animal treatment. Procedures for animal care were approved by the
University of Michigan committee on use and care of animals. Male Wistar rats
(150–200 g; Harlan, Indianapolis, IN) were provided with rodent chow (Lab
Diet; PMI Nutritional International, Brentwood, MO) and water ad libitum
until 1700 the night before the experiment, when their food was removed. The
next day, between 1000 and 1300, rats were anesthetized (intraperitoneal
injection of sodium pentobarbital, 60 mg/kg wt). While rats were deeply
anesthetized, both epitrochlearis muscles were rapidly extracted.
Muscle treatment. Isolated epitrochlearis muscles were preincubated in
Krebs-Henseleit buffer (KHB)  0.1% BSA  8 mmol/l glucose (solution 1) in
a water bath at 35°C with continuous gassing (95% O2/5% CO2). During this
step, one muscle per rat was incubated in solution 1 with either 500 nmol/l
Wortmannin (30 min) or 40 mol/l compound C (60 min); stock solutions of
each inhibitor were dissolved in vehicle (DMSO), and the contralateral muscle
was incubated in solution 1 containing vehicle (Wortmannin, 0.05% DMSO;
compound C, 0.4% DMSO). Inhibitors or vehicle remained at the same
concentration throughout subsequent incubations. Some muscles were trans-
ferred to vials containing identical media for 20 min (basal). Other muscles
were attached to a glass rod and force transducer (Radnoti, Litchﬁeld, CT) as
previously described (31). Mounted muscles were incubated in solution 1 with
gassing (95% O2/5% CO2) and stimulated to contract as previously described
(20 min, 2 ms pulse, 120 pulses/min, 25V; Grass S48 stimulator; Grass
Instruments, Quincy, MA) (19). Immediately afterward, muscles were either
freeze-clamped or transferred to vials containing KHB  2 mmol/l pyruvate 
36 mmol/l mannitol (solution 2; 30°C, 10 min) before 3-MG transport
measurement.
In separate experiments, muscles preincubated with inhibitors or vehicle
were transferred to vials with solution 1 supplemented with either insulin
(2,000 U/ml, 20 min) or 5-aminoimidazole-4-carboxamide-1--D-ribofurano-
side (AICAR; 2 mmol/l, 40 min). Muscles were then either freeze-clamped or
transferred to vials with solution 2 for 10 min before 3-MG transport
measurement.
Measurement of 3-MG transport. After 10-min incubation in solution 2,
muscles were transferred to ﬂasks containing KHB, 0.1% BSA with 8 mmol/l
3-MG (including [
3H]3-MG at a ﬁnal speciﬁc activity of 0.25 mCi/mmol), and 2
mmol/l mannitol (including [
14C]mannitol at a ﬁnal speciﬁc activity of 6.25
Ci/mmol) (32). After 10 min, muscles were rapidly blotted, trimmed, freeze-
clamped, and stored (80°C) until processed.
Homogenization. Muscles used for glucose transport and immunoblotting
were homogenized in 1 ml ice-cold homogenization buffer (20 mmol/l Tris-
HCl, pH 7.4, 150 mmol/l NaCl, 1% Igepal CA-639, 2 mmol/l Na3VO4, 2 mmol/l
EDTA, 2 mmol/l EGTA, 2.5 mmol/l sodium pyrophosphate, 20 mmol/l
-glycerophosphate, 2 mmol/l phenylmethanesulphonylﬂuoride, and 1 g/ml
leupeptin) using glass-on-glass tubes (Kontes, Vineland, NJ). Homogenates
were rotated (4°C, 1 h) before being centrifuged (12,000g, 10 min, 4°C).
Aliquots of supernatant used for 3-MG transport measurement were pipetted
into vials for scintillation counting, and 3-MG transport was determined (32).
A portion of supernatant was used to determine protein concentration per the
manufacturer’s instructions (catalog no. 23227; Pierce Biotechnology). Re-
maining supernatant was stored at 80°C until further analysis.
Immunoprecipitation. Muscles to be immunoprecipitated by anti-PAS or
anti-TBC1D1 were homogenized in T-PER–supplemented homogenization
buffer (2 mmol/l Na3VO4, 2 mmol/l EDTA, 2 mmol/l EGTA, 2.5 mmol/l sodium
pyrophosphate, 1 mmol/l -glycerophosphate, 1 mmol/l phenylmethanesul-
phonylﬂuoride, and 1 g/ml leupeptin in T-PER). Homogenate (300–500 g
protein) was mixed with Preclearing Matrix F (30 min), and the supernatant
was immunoprecipitated with 1.5–2 g of anti-PAS, anti-AS160, or anti-
TBC1D1 (4°C) using ExactaCruz F-HRP. After gentle rotation overnight, the
immunoprecipitation mix was centrifuged (4,000g), and supernatant was
aspirated. After washing (four times with 500 l PBS), protein bound to beads
was eluted with 2 Laemmli sample buffer, boiled, and loaded on a polyacryl-
amide gel.
Immunoblotting. Immunoprecipitates or lysate, boiled with SDS loading
buffer, were separated and electrophoretically transferred to nitrocellulose.
Samples were rinsed with Tris-buffered saline plus Tween (TBST; 0.14 mol/l
NaCl, 0.02 mol/l Tris base, pH 7.6, and 0.1% Tween 20), blocked with 5% nonfat
dry milk in TBST (1 h, room temperature), washed 3  5 min (room
temperature), and treated with primary antibodies (1:1,000 in TBST  5%
BSA) overnight (4°C). Blots were washed 3  5 min with TBST, incubated
with the secondary antibody (goat anti-rabbit IgG HRP conjugate, 1:20,000 in
TBST  5% milk,1ha troom temperature), washed again 3  5 min with
TBST, and developed with West Dura extended duration substrate reagent.
Protein bands were quantitated by densitometry (Alpha Innotech, San Lean-
dro, CA). Mean values for basal muscles incubated without inhibitors on each
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normalized basal value.
Statistical analysis. Statistical analyses used Sigma Stat version 2.0 (San
Rafael, CA). Data are expressed as the mean  SE, and P  0.05 was
considered statistically signiﬁcant. One-way ANOVA and the Student-New-
man-Keuls post hoc test were used. When data failed the Levene Median test
for equal variance, the Kruskal-Wallis nonparametric ANOVA on ranks was
used with Dunn’s post hoc test.
RESULTS
Tension development. Neither Wortmannin nor com-
pound C affected peak force or total force (data not
shown).
Total protein abundance. For all comparisons of immu-
noblot band intensities, equal amounts of total protein or
of immunoprecipitate derived from equal amounts of total
protein were loaded in each lane. Abundance of total
proteins (Akt, GSK3, AMPK, ACC, CaMKII, AS160, and
TBC1D1) was unaltered by insulin, contraction, Wortman-
nin, and/or compound C (Fig. 1).
AS160 and TBC1D1 phosphorylation. As previously
shown (19), the anti-PAS immunoblot of muscle samples
(basal, insulin, or contraction) without prior immunopre-
cipitation contained multiple PAS bands, including the
following: 1) an anti-PAS band migrating at a location
above the 150 kDa molecular marker (PAS-160) that
corresponded to the location of the anti-AS160 band from
an AS160 immunoblot and 2) an anti-PAS band migrating
at a location similar to the 150 kDa molecular marker
(PAS-150) and corresponding with the location of the
anti-TBC1D1 band from a TBC1D1 immunoblot (data not
shown). When samples were immunoprecipitated with
anti-PAS and immunoblotted with anti-AS160, the location
of the band (PAS-AS160) corresponded to the location of
the PAS-160 band. When samples were immunoprecipi-
tated with anti-TBC1D1 and immunoblotted with anti-PAS,
the location of the band (PAS-TBC1D1) corresponded to
the location of the PAS-150 band. Throughout this report,
when samples were directly immunoblotted with anti-PAS,
the bands are referred to as PAS-160 or PAS-150, respec-
tively, whereas when samples are immunoprecipitated
before immunoblotting, the respective bands are referred
to as PAS-AS160 or PAS-TBC1D1.
Wortmannin. Incubation of skeletal muscle with Wortman-
nin for 30 min completely inhibited the insulin-stimulated
increases in pAkt and pGSK3 (P 	 0.001) (Fig. 2A and B).
Insulin (with or without Wortmannin) did not alter pAMPK,
pACC, or pCaMKII (data not shown). Insulin-stimulated
increases in PAS-160 (Fig. 2C), PAS-150 (Fig. 2D), and
glucose transport (Fig. 2E) were completely inhibited by
Wortmannin (P 	 0.001).
Contraction resulted in a signiﬁcant increase in glucose
transport, pGSK3, pAMPK, pACC, and pCaMKII (P 	 0.05)
(Figs. 3 and 4) as well as PAS-160 and PAS-150 (data not
shown). PAS-AS160 and PAS-TBC1D1 were also signiﬁ-
cantly (P 	 0.05) elevated after contraction compared
with basal muscles (Fig. 3F and G). Consistent with
previous results using this contraction protocol (19), there
was a nonsigniﬁcant trend for a small contraction-stimu-
lated increase in pAkt (Fig. 3A and 4A). There were no
contraction effects on pAkt and pGSK3 in Wortmannin-
treated muscles (Fig. 3A and B)( P 	 0.05). Wortmannin
did not affect contraction-stimulated pAMPK, pACC, or
pCaMKII (Fig. 3C–E). Increases in PAS-AS160 (P 	 0.01)
(Fig. 3F) and PAS-160 (data not shown) in contraction-
stimulated muscles were eliminated with Wortmannin
treatment. In contrast, increases in PAS-TBC1D1 (Fig. 3G)
and PAS-150 (data not shown) in contraction-stimulated
muscles were not signiﬁcantly affected by Wortmannin
FIG. 1. Abundance of total proteins (Akt, GSK3, AMPK, ACC, CaMKII, AS160, and TBC1D1). There were no statistically signiﬁcant differences
among groups (n  4 per group) for total protein abundance in muscles with or without insulin and/or Wortmannin (A), contraction and/or
Wortmannin (B), and contraction and/or compound C (C). CC, compound C; Wort, Wortmannin.
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stimulated muscles was unaltered by Wortmannin (Fig.
3H).
Compound C. Compound C caused complete inhibition of
the contraction-stimulated increase in pACC (P 	 0.001)
(Fig. 4D) without affecting pAkt, pGSK3, and pCaMKII
(Fig. 4A, B, and E). Compound C did not signiﬁcantly alter
the increased PAS-AS160 (Fig. 4F) or PAS-160 (data not
shown) in contraction-stimulated muscles. In contrast,
compound C signiﬁcantly reduced the increases in PAS-
TBC1D1 (P 	 0.05) (Fig. 4G) and PAS-150 (data not
shown) in contraction-stimulated muscles. The increase in
glucose transport in contraction-stimulated muscles was
partially reduced by compound C (P 	 0.001) (Fig. 4H).
Insulin-stimulated glucose transport was unaffected by
compound C (Fig. 5A), and the increase in glucose trans-
port in AICAR-stimulated muscles was completely elimi-
nated by compound C (P 	 0.01) (Fig. 5B).
DISCUSSION
This study provides new information about the regulation
and function of AS160 and TBC1D1, two related RabGAP
proteins expressed by skeletal muscle, each of which has
been implicated to modulate glucose transport. The re-
sults demonstrate that it is possible to separate contrac-
tion’s ability to increase AS160 phosphorylation from
TBC1D1 phosphorylation, as identiﬁed using the PAS
antibody, and reveal novel insights regarding their respec-
tive roles in the activation of glucose transport. The data
suggest that in isolated rat epitrochlearis muscle: 1)P I
3-kinase–dependent (and presumably Akt-dependent)
mechanisms are essential for the insulin-stimulated in-
creases in glucose transport and phosphorylation of AS160
and TBC1D1, 2) PI 3-kinase/Akt–dependent (but not
AMPK-dependent) mechanisms are essential for the con-
traction-stimulated increase in PAS-AS160 (but not PAS-
TBC1D1 or glucose transport), and 3) AMPK-dependent
(but not PI 3-kinase/Akt–dependent) mechanisms are es-
sential for the contraction-stimulated increases in PAS-
TBC1D1 (but not PAS-AS160) and glucose transport. The
ﬁndings support the idea that elevated PAS-TBC1D1, via
an AMPK-dependent mechanism, may participate in con-
traction-mediated glucose transport.
Regarding insulin stimulation, the data are consistent
with earlier research in 3T3-L1 adipocytes (13,16,33),
human primary myocytes (34), and rodent skeletal muscle
(18,28), which indicated that the insulin stimulation of
PAS-AS160 is Akt dependent. Our results conﬁrm that
insulin can induce increased PAS-TBC1D1 in skeletal
muscle (24). Wortmannin has been shown to reduce
)
FIG. 2. Effects of Wortmannin on insulin-stimulated phosphorylation of Akt
Thr308 (A), GSK3
Ser21/9 (B), PAS-160 (C), PAS-150 (D), and glucose
transport (E). Paired isolated rat epitrochlearis muscles were incubated with or without 500 nmol/l of Wortmannin for 30 min. Muscles were then
either incubated in identical media (basal) or in solution that contained 2,000 U/ml of insulin for 20 min, freeze-clamped immediately, and used
for immunoblotting or for 3-MG transport measurement. Data are the means  SE, n  5–9 per group. Post hoc analysis: *P < 0.05 (effect of
insulin); †P < 0.05 (effect of Wortmannin). e, DMSO; f, Wortmannin. Wort, Wortmannin.
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the current data are apparently the ﬁrst demonstration in
an authentic insulin target tissue that Wortmannin-induced
inhibition of Akt eliminates the insulin-stimulated increase
in PAS-150, which corresponds to PAS-TBC1D1.
Contraction for 20 min caused an increase in phosphor-
ylation of GSK3, an Akt substrate, despite only a trend for
increased Akt phosphorylation. These results are consis-
tent with previous observations indicating that contractile
activity can transiently activate Akt, achieving peak activ-
ity and phosphorylation at 2–5 min with reversal at
15–20 min, despite continued stimulation (19,35). In
rat epitrochlearis, contraction-stimulated PAS-AS160 was
completely Wortmannin inhibitable, suggesting that con-
traction-stimulated AS160 Pas phosphorylation is PI 3-ki-
nase/Akt–dependent, as previously reported (18). The
current results conﬁrm recent studies that found contrac-
tion causes an increase in skeletal muscle PAS-TBC1D1
(19,24). In striking contrast to AS160, Wortmannin did not
attenuate the contraction-stimulated increase in PAS-
TBC1D1, suggesting that contraction’s effect on PAS-
TBC1D1 was not PI 3-kinase/Akt–dependent. Furthermore,
the AMPK inhibitor compound C completely suppressed
contraction-stimulated PAS-TBC1D1 without inhibiting con-
traction’s effect on PAS-AS160. Notably, Wortmannin did not
alter phosphorylation of AMPK or ACC (an AMPK substrate),
and compound C did not alter phosphorylation of Akt or
GSK3 (an Akt substrate). These experiments reveal funda-
mental differences in mechanisms whereby contraction reg-
ulates phosphorylation of two closely related RabGAP
proteins.
The data provide new evidence that increased PAS-
TBC1D1 in skeletal muscle with contraction is AMPK
dependent. Supporting this interpretation, incubating skel-
etal muscle with AICAR induced an increase in PAS-
TBC1D1, and incubation of recombinant AMPK with
immunoprecipitated TBC1D1 caused increased PAS-
TBC1D1 (24). Earlier studies that found that muscle from
mice with genetically disrupted AMPK had reduced con-
traction-stimulated phosphorylation at 160 kDa had not
performed immunoprecipitation of samples before immu-
noblotting with the PAS antibody (28,29). Perhaps in these
FIG. 3. Effects of Wortmannin on contraction-stimulated phosphorylation of Akt
Thr308 (A), GSK3
Ser21/9 (B), AMPK
Thr172 (C), ACC
Ser79 (D),
CaMKII
Thr286 (E), PAS-AS160 (F), PAS-TBC1D1 (G), and glucose transport (H). Paired isolated rat epitrochlearis muscles were incubated with
or without 500 nmol/l of Wortmannin for 30 min. Muscles were then either rested (basal) or stimulated to contract for 20 min, freeze-clamped
immediately for immunoprecipitation (IP) and/or immunoblotting (IB), or used for 3-MG transport measurement. Data are the means  SE, n 
9–17 per group. Post hoc analysis: *P < 0.05 (effect of contraction); †P < 0.05 (effect of Wortmannin). e, DMSO; f, Wortmannin. Wort,
Wortmannin.
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and AS160, with TBC1D1 accounting for at least a portion
of the apparently AMPK-dependent phosphorylation.
A secondary aim was to determine whether inhibition of
insulin- or contraction-stimulated increases in PAS-AS160
or PAS-TBC1D1 were accompanied by attenuation of
glucose transport. A great deal of evidence supports the
idea that the insulin-stimulated increase in AS160 phos-
phorylation, via a PI 3-kinase/Akt–dependent mechanism,
is important for increased GLUT4 translocation and glu-
cose transport (13–18,33). The current data are consistent
with this role of AS160. Few studies have evaluated
TBC1D1’s possible role in insulin-stimulated glucose trans-
port. In 3T3-L1 adipocytes, knockdown of TBC1D1 did not
alter basal or insulin-stimulated GLUT4 in surface mem-
branes (23). However, these results are not necessarily
predictive of skeletal muscle, which, compared with
3T3-L1 cells, expresses TBC1D1 at much greater levels
(23). In L6 myotubes, knockdown of TBC1D1 resulted in
elevated basal surface GLUT4 and a 1.5-fold elevation in
insulin-stimulated GLUT4 translocation (25). The authors’
interpretation was that TBC1D1 can modulate GLUT4
trafﬁc, but insulin may not regulate TBC1D1’s RabGAP
activity. The current data demonstrate that insulin regu-
lates TBC1D1 phosphorylation in skeletal muscle via a PI
3-kinase/Akt–dependent mechanism, but the functional
consequences of TBC1D1 phosphorylation on glucose
transport remain uncertain.
Because contraction-stimulated glucose transport was
unaltered by Wortmannin, despite elimination of the in-
crease in PAS-AS160, it is evident that increased PAS-
AS160 is not essential for contraction-mediated glucose
transport. The lack of a Wortmannin effect on contraction-
stimulated increases in PAS-TBC1D1 and glucose trans-
port, together with compound C inducing full inhibition of
contraction’s effect on PAS-TBC1D1 and partial inhibition
of glucose transport, is consistent with the possibility that
PAS-TBC1D1 participates in the contraction-stimulated
increase in glucose transport. However, the current results
do not establish causality, and although compound C did
FIG. 4. Effects of compound C on contraction-stimulated phosphorylation of Akt
Thr308 (A), GSK3
Ser21/9 (B), AMPK
Thr172 (C), ACC
Ser79 (D),
CaMKII
Thr286 (E), PAS-AS160 (F), PAS-TBC1D1 (G), and glucose transport (H). Paired isolated rat epitrochlearis muscles were incubated with or
without 40 mol/l of compound C for 60 min. Muscles were then either rested (basal) or stimulated to contract for 20 min, freeze-clamped immediately
for immunoprecipitation (IP) and/or immunoblotting (IB), or used for 3-MG transport measurement. Data are the means  SE, n  6–14 per group. Post
hoc analysis: *P < 0.05 (effect of contraction); †P < 0.05 (effect of compound C). e, DMSO; f, compound C. CC, compound C.
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PAS-AS160, these results do not prove that compound C’s
effects are exclusively attributable to inhibiting AMPK.
Wortmannin can completely inhibit contraction’s activa-
tion of Akt in skeletal muscle without reducing contrac-
tion-stimulated glucose transport (7,8,36). Another PI
3-kinase inhibitor, LY294002, also inhibits contraction-
activated Akt (35). These results with two distinct PI
3-kinase inhibitors suggest that PI 3-kinase is upstream of
contraction-stimulated Akt. However, muscle contraction
does not increase class Ia PI 3-kinase activity associated
with insulin receptor substrate proteins (10) or class II PI
3-kinase activity (37). Sakamoto et al. (35) proposed that
contraction may activate class Ib PI 3-kinase, but this
possibility remains to be experimentally conﬁrmed. Nev-
ertheless, Wortmannin can clearly eliminate contraction-
stimulated increases in pAkt and PAS-AS160 in rat
epitrochlearis muscle, which begs the question: How can
activation of Akt and PAS-AS160 be important for insulin-
stimulated glucose transport, but not contraction-stimu-
lated glucose transport? A similar paradox is that either
insulin or contraction can individually lead to increased
glucose transport in skeletal muscle by increasing GLUT4
translocation, but the combined stimulation of muscle
with maximally effective insulin and contraction can in-
crease glucose transport (38,39) and cell-surface GLUT4
(39) more than either stimulus alone. There is evidence
suggesting that insulin and contraction recruit different
intracellular pools of GLUT4 vesicles (1,2). Little is known
about subcellular localization of AS160 or TBC1D1, but it
has been reported that in 3T3-L1 adipocytes, AS160 ap-
pears to be associated with GLUT4 vesicles under basal
conditions, and insulin treatment can cause an increase in
cytosolic AS160 (40). A speculative scenario is that insulin-
recruitable GLUT4 vesicles may associate with AS160,
whereas contraction-associated GLUT4 vesicles may asso-
ciate with TBC1D1. In addition, AS160 and TBC1D1 func-
tion are likely also regulated by other mechanisms,
including 1) phosphorylation on sites undetectable with
anti-PAS, 2)C a
2-calmodulin interaction with each pro-
tein’s calmodulin binding domain, 3) binding to 14-3-3
proteins, and 4) changes in subcellular localization
(21,26,27,40–43). Evaluation of these and alternative
mechanisms will be necessary to fully understand the
regulation and roles of AS160 and TBC1D1.
We also determined whether acute inhibition of the
contraction-stimulated activation of AMPK would result in
attenuated glucose transport. AMPK was originally recog-
nized as a potential participant in contraction-stimulated
glucose transport by Winder and colleagues (44–46). They
found that exercise or contraction can activate AMPK
(44,45), and AICAR, which also leads to AMPK activation,
can stimulate glucose uptake (46). Many studies have
supported a role for AMPK in contraction-stimulated glu-
cose transport (4,11,12,47), but research using mice with
genetic modiﬁcation of AMPK suggests that AMPK may
not be essential for contraction-stimulated glucose trans-
port (48,49). With genetic modiﬁcations, there may be
compensatory responses. Compound C, which offers a
useful alternative approach for rapid inhibition of AMPK,
resulted in reduced contraction-stimulated glucose trans-
port, providing novel evidence that AMPK may be impor-
tant for this contraction effect.
The partial reduction in contraction-stimulated glucose
transport by compound C supports earlier studies that
indicated that AMPK-independent mechanisms can ac-
count for a portion of the contraction-stimulated glucose
transport (11,12). Multiple lines of evidence suggest that
increased cytosolic calcium contributes to contraction-
stimulated glucose transport (12,41). For example, cal-
modulin binding to AS160 has been implicated in
contraction-stimulated glucose transport (41). TBC1D1
also contains a calmodulin binding domain (21). Unaltered
contraction-stimulated increases in pCaMKII and tension
in compound C–treated muscles suggest that cytosolic
Ca
2 was not reduced, which may account, at least in part,
for the residual effect of contraction on glucose transport.
AICAR can activate AMPK without altering cytosolic Ca
2
concentration in isolated rat epitrochlearis (50). In this
context, it is notable that, in contrast to the partial inhibition
of contraction-stimulated glucose transport, compound C
completely inhibited AICAR-stimulated glucose transport.
Furthermore, compound C had no effect on insulin-stimu-
lated glucose transport, indicating that compound C’s ability
to reduce glucose transport activated by contraction or
FIG. 5. Effects of compound C on insulin-stimulated (A) and AICAR-stimulated (B) glucose transport. Paired isolated rat epitrochlearis muscles
were incubated with or without 40 mol/l of compound C for 60 min. Muscles were then either incubated in identical media (basal) or in solution
that contained 2,000 U/ml of insulin (A) for 20 min or in solution that contained 2 mmol/l of AICAR (B) for 40 min and used for 3-MG transport
measurement. Data are the means  SE, n  6–14 per group. Post hoc analysis: *P < 0.05 (effect of insulin or AICAR); †P < 0.05 (effect of
compound C). e, DMSO; f, compound C.
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transport, regardless of the stimulation pathway.
The contraction-stimulated increases in PAS-TBC1D1
and glucose transport with 20 min of contractile activity in
the current study are similar to earlier results using the
same contraction protocol (19). The previous study, which
included assessment for up to 60 min of contraction, found
that the glucose transport rate achieved with 20 min of
contraction was sustained with contraction lasting 60 min,
even though contraction-stimulated PAS-TBC1D1 had re-
turned to basal levels at 60 min (19). These results suggest
PAS-TBC1D1 may trigger the initial increase in contrac-
tion-stimulated glucose transport. It remains unclear
whether the initial increase in PAS-TBC1D1 is sufﬁcient to
cause a sustained increase in contraction-stimulated glu-
cose transport or whether another mechanism is required
for a sustained increase.
In conclusion, Fig. 6 represents our Working model for
increasing PAS-AS160 and PAS-TBC1D1 with insulin or
contraction, and for the roles that insulin- or contraction-
stimulated PAS-AS160 and PAS-TBC1D1 may play in the
regulation of glucose transport. We found that: 1) insulin
stimulates Pas phosphorylation of AS160 and TBC1D1 in an
Akt-dependent manner, and PAS-AS160 appears to be impor-
tant for the regulation of insulin-stimulated glucose transport
with the functional role of insulin-stimulated PAS-TBC1D1
currently uncertain; 2) contraction stimulates PAS-phosphory-
lation of AS160, but not TBC1D1, in an Akt-dependent
manner, and the contraction-stimulated PAS-AS160 does not
contribute to contraction-stimulated glucose transport; and
3) contraction stimulates Pas phosphorylation of TBC1D1 in
an AMPK-dependent manner, consistent with the idea that
contraction-stimulated PAS-TBC1D1 may regulate contrac-
tion-stimulated glucose transport. Additional research with
speciﬁc manipulation of TBC1D1 expression and/or activa-
tion will be needed to further elucidate TBC1D1’s role in
glucose transport of skeletal muscle.
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